Kidney stone prevention
First line
Potassium citrate is first-line for prevention of recurrent calcium oxalate, uric acid and cystine stones in patients with hypocitraturia, low urinary pH or recurrent urolithiasis. The Cochrane review 2015 pooled 7 RCTs with 477 patients and showed citrate salts reduce new-stone risk by 75 % versus placebo or control (RR 0.25, 95 % CI 0.14–0.44). Guidelines AUA 2014, EAU 2024 and Spanish AEU 2024 recommend potassium citrate 30–60 mEq/day as first-line after 24-hour urine assessment. Targets: urinary citrate above 320 mg/day, urinary pH 6.0–7.0. In gouty uric-acid nephropathy allopurinol adds benefit. AEMPS registered Acalka with this indication.